Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions

European Heart Journal

Volumn 31, Issue 1, 2010, Pages 59-66

  Geisler, Tobias ^a   Zürn, Christine ^a   Simonenko, Rostislav ^a   Rapin, Mathilde ^a   Kraibooj, Hassan ^a   Kilias, Antonios ^a   Bigalke, Boris ^a   Stellos, Konstantinos ^a   Schwab, Matthias ^a   May, Andreas E ^a   Herdeg, Christian ^a   Gawaz, Meinrad ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Aggregation; Antiplatelet drug resistance; Clopidogrel; Percutaneous coronary intervention; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; HEPARIN; RAPAMYCIN; TACROLIMUS; ZOTAROLIMUS;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; CORRELATION ANALYSIS; DRUG ELUTING STENT; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; KAPLAN MEIER METHOD; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADOLESCENT; ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73949100670     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp402     Document Type: Article

References (31)

1. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-2425.
2. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750.
3. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549.
4. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46: 1820-1826.
5. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabaté M, Escaned J, Bañuelos C, Fernández-Ortiz A, Macaya C. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-959.
6. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371:1353-1363.
7. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293:2126-2130.
8. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a metaa-nalysis. Eur Heart J 2006;27:2784-2814.
9. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PP, de Feyter P, van Domburg RT, Serruys PW. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-953.
10. Park D-W, Park S-W, Park K-H, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-356.
11. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clo-pidogrel effect on platelet reactivity in patients with stent thrombosis. J Am Coll Cardiol 2005;46:1827-1832.
12. Wenaweser P, Dörffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, Haeberli A, Hess OM. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748-1752.
13. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49: 2312-2317.
14. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115: 2344-2351.
15. Müller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schö mig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85:92-93.
16. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Büttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-2564.
17. Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998;80: 994-1001.
18. Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schomig A, Gawaz M. Antiplate-let effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001;37:1323-1328.
19. Machecourt J, Danchin N, Lablanche JM EVASTENT Investigators. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and non-diabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007;50:501-508.
20. Schühlen H, Kastrati A, Pache J, Dirschinger J, Schömig A. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol 2001;37:2066-2073.
21. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
22. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913.
23. Geisler T, Kapp M, Göhring-Frischholz K, Daub K, Dösch C, Bigalke B, Langer H, Herdeg C, Gawaz M. Residual platelet activity is increased in clopidogrel-and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008;94:743-747.
24. Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clo-pidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.
25. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221-231.
26. Palmerini T, Coller BS, Cervi V, Tomasi L, Marzocchi A, Marrozzini C, Leone O, Piccioli M, Branzi A. Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system. J Am Coll Cardiol 2004;44:1570-1577.
27. Cheneau E, Leborgne L, Mintz GS, Kotani J, Pichard AD, Satler LF, Canos D, Castagna M, Weissman NJ, Waksman R. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 2003;108:43-47.
28. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, Herdeg C, Gawaz M. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008;6:54-61.
29. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ. Cytochrome P450 2C19 681G.A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51: 1925-1934.
30. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, Zuern C, Moerike K, Gawaz M, Schwab M. Cytochrome P450 2C19 and non-genetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008;9:1251-1259.
31. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362.